PROTHENA CORPORATION PUBLIC LIMITED COMPANY Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $426.00K, a 84.29% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $591.00K, a 96.23% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $890.00K, a 64.96% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY stock issued during period, value, stock options exercised for the quarter ending 2023-09-30 was $2.71M, a 64.15% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY stock issued during period, value, stock options exercised for fiscal 2024 was $1.91M, a 91.11% decline from fiscal 2023.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY stock issued during period, value, stock options exercised for fiscal 2023 was $21.46M, a 19.94% increase from fiscal 2022.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY stock issued during period, value, stock options exercised for fiscal 2022 was $17.89M, a 15.00% increase from fiscal 2021.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY stock issued during period, value, stock options exercised for fiscal 2021 was $15.56M, a 7135.81% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2024-12-31 | $1.91M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $426.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $591.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $890.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $21.46M 10-K · filed 2026-02-27 | |
| 2023-09-30 | $2.71M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $15.66M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $2.54M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $17.89M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $7.56M 10-Q · filed 2023-11-02 | $11.33M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $427.00K 10-Q · filed 2023-11-02 | $7.90M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $1.48M 10-Q · filed 2023-11-02 | $13.95M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $15.56M 10-K · filed 2024-02-22 |
| 2021-09-30 | $4.13M 10-Q · filed 2022-11-03 | $13.69M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $6.48M 10-Q · filed 2022-11-03 | $9.63M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $3.08M 10-Q · filed 2022-11-03 | $3.15M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $215.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | $64.00K 10-Q · filed 2021-11-04 | $228.00K derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $164.00K derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $151.00K 10-Q · filed 2021-05-11 | $374.00K derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $228.00K 10-K · filed 2022-02-25 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $215.00K derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $210.00K 10-Q · filed 2020-08-06 | $428.00K derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $5.00K 10-Q · filed 2020-05-06 | $292.00K derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $4.69M 10-K · filed 2021-02-26 |
| 2018-09-30 | $213.00K 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $74.00K 10-Q · filed 2019-08-06 | |
| 2018-03-31 | $4.40M 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $17.84M 10-K · filed 2020-03-03 | |
| 2016-12-31 | $10.52M 10-K · filed 2019-03-15 | |
| 2015-12-31 | $5.64M 10-K · filed 2018-02-26 | |
| 2014-12-31 | $501.00K 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |